Niemann-Pick disease types A and B (NORD)

5,680views

Niemann-Pick disease types A and B (NORD)

Cardiovascular

Cardiovascular

Development of the cardiovascular system
Anatomy of the heart
Anatomy of the superior mediastinum
Anatomy of the inferior mediastinum
Anatomy of the coronary circulation
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Mediastinum
Pressures in the cardiovascular system
Hyperlipidemia
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Beckwith-Wiedemann syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Familial hypercholesterolemia
Hereditary spherocytosis
Li-Fraumeni syndrome
Marfan syndrome
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Gaucher disease (NORD)
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Hemochromatosis
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Krabbe disease
Leukodystrophy
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Primary ciliary dyskinesia
Sickle cell disease (NORD)
Tay-Sachs disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
Alport syndrome
X-linked agammaglobulinemia
Fabry disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Lesch-Nyhan syndrome
Muscular dystrophy
Ornithine transcarbamylase deficiency
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review
Hypertension
Baroreceptors
Lipid-lowering medications: Statins
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Microcirculation and Starling forces
ECG basics
ECG intervals
ECG axis
ECG normal sinus rhythm
ECG QRS transition
ECG rate and rhythm
ECG cardiac hypertrophy and enlargement
ECG cardiac infarction and ischemia
Renin-angiotensin-aldosterone system
Myocardial infarction
Tetralogy of Fallot
Atrial septal defect
Ventricular septal defect
Thiazide and thiazide-like diuretics
Adrenergic antagonists: Beta blockers
Calcium channel blockers
ACE inhibitors, ARBs and direct renin inhibitors
Abnormal heart sounds
Normal heart sounds
Action potentials in myocytes
Excitability and refractory periods
Action potentials in pacemaker cells
Cardiac excitation-contraction coupling
Cardiac conduction velocity
Cardiac conduction system
Persistent truncus arteriosus
Atrial fibrillation
Ventricular tachycardia
Ventricular fibrillation
Atrioventricular block
Bundle branch block
Heart failure
Long QT syndrome and Torsade de pointes
Aortic valve disease
Mitral valve disease
Loop diuretics
Peripheral artery disease

Transcript

Watch video only

Content Reviewers

Niemann-Pick disease type A and type B, or NPD-A and NPD-B, which are subtypes of acid sphingomyelinase or ASM deficiency, are rare, genetically inherited conditions characterized by the inability to break down a fat called sphingomyelin due to a deficiency of the enzyme, acid sphingomyelinase.

There’s also Niemann-Pick disease type C, which is known to be caused by mutations in the genes NPC1 and NPC2, and is therefore considered to be distinct from types A and B.

Sphingomyelin is a fat that's included in the membrane of many different cells.

When cells become old or damaged, they are often phagocytized, or eaten, by macrophages, which are cells of the immune system.

They contain organelles called lysosomes that are said to function as recycling centers because they break down large, potentially harmful substances to be reused by the body.

They break down sphingomyelin by using an enzyme called acid sphingomyelinase, which is a product of the sphingomyelin phosphodiesterase 1, or SMPD1 gene.

In Niemann-Pick disease types A and B, there’s a mutation in the SMPD1 gene that causes a defect in the production of sphingomyelinase, leading to an inability to break down sphingomyelin.

In NPD-A there’s almost a complete absence of sphingomyelinase activity, while NPD-B has some residual sphingomyelinase activity remaining.

While the mechanism isn’t completely understood, sphingomyelin primarily accumulates in the lysosomes of macrophages, which travel throughout the body and cause damage in multiple organs and tissues.

The macrophages develop a characteristic lipid-laden appearance under microscopes and are called “foam cells.”

Sphingomyelin can also build up in other cell types in the body, reflecting impaired intracellular recycling of membranes and damaged organelles in lysosomes due to sphingomyelinase deficiency.

Signs and symptoms of NPD-A present early in life, and are usually life-threatening.

These include enlargement of the liver and/or spleen, jaundice, feeding difficulties, and progressive loss of reflexes and muscle tone.

Infants also often develop a “cherry red spot” in the eye that affects the macula, which corresponds with a decrease in central vision.

Key Takeaways

Niemann-Pick disease (NPD) type A and type B, are rare inherited conditions characterized by the inability to break down sphingomyelin, due to a deficiency of the enzyme acid sphingomyelinase. Niemann-Pick disease type A and type B result from SMPD1 gene mutation, which normally encodes to sphingomyelinase enzyme.

NPD-A symptoms present early in life and may include hepatosplenomegaly, jaundice, feeding difficulties, and progressive loss of reflexes and muscle tone. It is also often associated with a cherry red spot � in the eye, which affects the macula and impairs central vision. Usually, NPD-A becomes fatal by the age of 3 years old.

On the other hand, NPD-B represents a less severe condition that typically does not include neurologic involvement, and can develop at any time in life. Common NPD-B symptoms include progressive splenomegaly, which causes low serum platelet and white blood cell levels, high cholesterol, and declining lung function. There is no cure for NPA and NPB, and treatment is supportive and focuses on managing symptoms.